160 related articles for article (PubMed ID: 22203731)
1. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.
Kim H; Zhai G; Samuel SL; Rigell CJ; Umphrey HR; Rana S; Stockard CR; Fineberg NS; Zinn KR
Mol Cancer Ther; 2012 Feb; 11(2):405-15. PubMed ID: 22203731
[TBL] [Abstract][Full Text] [Related]
2. (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts.
Shah N; Zhai G; Knowles JA; Stockard CR; Grizzle WE; Fineberg N; Zhou T; Zinn KR; Rosenthal EL; Kim H
Mol Imaging Biol; 2012 Apr; 14(2):237-44. PubMed ID: 21494920
[TBL] [Abstract][Full Text] [Related]
3. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.
DeRosier LC; Buchsbaum DJ; Oliver PG; Huang ZQ; Sellers JC; Grizzle WE; Wang W; Zhou T; Zinn KR; Long JW; Vickers SM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5535s-5543s. PubMed ID: 17875786
[TBL] [Abstract][Full Text] [Related]
5. A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models.
Kim H; Buchsbaum DJ; Zinn KR
Mol Imaging Biol; 2016 Jun; 18(3):325-33. PubMed ID: 26552657
[TBL] [Abstract][Full Text] [Related]
6. Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy.
Kim H; Zhai G; Liu Z; Samuel S; Shah N; Helman EE; Knowles JA; Stockard CR; Fineberg NS; Grizzle WE; Zhou T; Zinn KR; Rosenthal EL
Anticancer Drugs; 2011 Oct; 22(9):864-74. PubMed ID: 21730821
[TBL] [Abstract][Full Text] [Related]
7. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
[TBL] [Abstract][Full Text] [Related]
8. Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers.
Kim H; Rigell CJ; Zhai G; Lee SK; Samuel SL; Martin A; Umphrey HR; Stockard CR; Beasley TM; Buchsbaum DJ; Li LS; Boothman DA; Zinn KR
Mol Imaging Biol; 2014 Feb; 16(1):85-94. PubMed ID: 23836505
[TBL] [Abstract][Full Text] [Related]
9. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.
Derosier LC; Vickers SM; Zinn KR; Huang Z; Wang W; Grizzle WE; Sellers J; Stockard CR; Zhou T; Oliver PG; Arnoletti P; Lobuglio AF; Buchsbaum DJ
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3198-207. PubMed ID: 18089714
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of (89)Zr-labeled human anti-CD147 monoclonal antibody as a positron emission tomography probe in a mouse model of pancreatic cancer.
Sugyo A; Tsuji AB; Sudo H; Nagatsu K; Koizumi M; Ukai Y; Kurosawa G; Zhang MR; Kurosawa Y; Saga T
PLoS One; 2013; 8(4):e61230. PubMed ID: 23577210
[TBL] [Abstract][Full Text] [Related]
12. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.
Kim H; Morgan DE; Buchsbaum DJ; Zeng H; Grizzle WE; Warram JM; Stockard CR; McNally LR; Long JW; Sellers JC; Forero A; Zinn KR
Cancer Res; 2008 Oct; 68(20):8369-76. PubMed ID: 18922909
[TBL] [Abstract][Full Text] [Related]
13. Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer.
Dean NR; Newman JR; Helman EE; Zhang W; Safavy S; Weeks DM; Cunningham M; Snyder LA; Tang Y; Yan L; McNally LR; Buchsbaum DJ; Rosenthal EL
Clin Cancer Res; 2009 Jun; 15(12):4058-65. PubMed ID: 19509148
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
[TBL] [Abstract][Full Text] [Related]
15. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
16. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.
Yuan K; Sun Y; Zhou T; McDonald J; Chen Y
Clin Cancer Res; 2013 Sep; 19(17):4750-9. PubMed ID: 23833311
[TBL] [Abstract][Full Text] [Related]
17. Effect of anti-DR5 and chemotherapy on basal-like breast cancer.
Oliver PG; LoBuglio AF; Zhou T; Forero A; Kim H; Zinn KR; Zhai G; Li Y; Lee CH; Buchsbaum DJ
Breast Cancer Res Treat; 2012 Jun; 133(2):417-26. PubMed ID: 21901385
[TBL] [Abstract][Full Text] [Related]
18. Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.
Kaliberov SA; Chiz S; Kaliberova LN; Krendelchtchikova V; Della Manna D; Zhou T; Buchsbaum DJ
Cancer Gene Ther; 2006 Feb; 13(2):203-14. PubMed ID: 16082379
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model.
Kendrick JE; Straughn JM; Oliver PG; Wang W; Nan L; Grizzle WE; Stockard CR; Alvarez RD; Buchsbaum DJ
Gynecol Oncol; 2008 Mar; 108(3):591-7. PubMed ID: 18177927
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
Bevis KS; McNally LR; Sellers JC; Della Manna D; LondoƱo Joshi A; Amm H; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2011 Apr; 121(1):193-9. PubMed ID: 21211830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]